Publication: Gene therapy for aromatic L-amino acid decarboxylase deficiency: Requirements for safe application and knowledge-generating follow-up
This original article, published in JIMD, explores the requirements and recommendations for patients who receive gene therapy for aromatic L-amino acid decarboxylase (AADC) deficiency
Learn more about AADC deficiency, a rare genetic disorder
Explore gene therapy as a treatment option for AADC deficiency
Review the consensus recommendations for intraputaminal gene therapy preparation, delivery, and management, including postoperative care
Roubertie A, et al. J Inherit Metab Dis. 2023. Epub ahead of print
▼ Eladocagene exuparvovec is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC Therapeutics at email@example.com.
Eladocagene exuparvovec (UpstazaTM) is a gene therapy indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of AADC deficiency with a severe phenotype, currently licensed in the European Member States, Great Britain, Iceland, Liechtenstein, Northern Ireland and Norway.
Registration conditions differ internationally; always consult local prescribing information and/or Summary of Product Characteristics before prescribing any product.
Once registered, you will be able to view the abstract and be provided with the DOI links for this publication.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-AADC-2300229 | January 2024
Sign in or register to access exclusive content on this site